Exosome-based therapies from mesenchymal stem cells for regenerative medicine.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Funding round EVerZom raised €10 million to start the first clinical trial of EVerGel against Crohn's perianal fistulas in 2026. | $11.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.